Shilpa Medicares Jadcherla Facility Receives US FDA Warning Letter
Shilpa Medicare Ltd has received a warning letter from US FDA for its Jadcherla facility, Telangana.The company said that it will be engaging with the agency and are fully committed in resolving this issue at the earliest.The company is also committed in maintaining the highest standards of compliances and quality manufacturing across all its facilities.The company believes that the warning letter will have minimum impact of disruption of supplies and the existing revenues from operations of this facility.The company currently has three manufacturing facilities approved by US FDA - One formulation facility and two API facilities. None of these facilities except Jadcherla has any outstanding issues with the US FDA at this point of time.
Optimize Your trial insights with Clival Database.
Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.
With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.
To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.
Elevate your trial success rate with the cutting-edge insights from Clival database.
Check it out today and make more informed sourcing decisions! Learn More!
